Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-07-11Clinical Trial Update: Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC [Phase 1, Phase 2]
Clinical trial updates on polaprezinc for castration-resistant prostate cancer resistant to enzalutamide or abiraterone, covering Phase 1 an…
-
FDA approval · 2023-07-07FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for JEVTANA (cabazitaxel) submitted by Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2023-06-28Clinical Trial Update: Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) [Phase 1]
Phase 1 trial evaluating oral rucaparib in combination with other anticancer agents in metastatic castration-resistant prostate cancer has c…
-
CLINICAL_TRIALS trial_result · 2023-06-18Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) [Phase 3]
Phase 3 trial comparing pembrolizumab plus docetaxel to placebo plus docetaxel in chemotherapy-naïve metastatic castration-resistant prostat…
-
CLINICAL_TRIALS trial_result · 2023-06-15Clinical Trial Update: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer [Phase 3]
Phase 3 trial investigating olaparib plus abiraterone as first-line therapy for metastatic castration-resistant prostate cancer.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-06-15Clinical Trial Update: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer [Phase 3]
Phase 3 study update evaluating olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer;…
-
CLINICAL_TRIALS trial_result · 2023-06-13Clinical Trial Update: SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]
Phase 2 clinical trial update for SHR7390 in metastatic hormone-resistant prostate cancer (metastatic castration-resistant prostate cancer) …
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 trial update reports results for Abemaciclib (Verzenio) in men with heavily treated metastatic castration-resistant prostate cancer.
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC [Phase 1, Phase 2]
Phase 1/2 trial evaluating CORT125281 in combination with enzalutamide in metastatic castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2023-04-24Clinical Trial Update: A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) [Phase 2]
This update reports results from the CheckMate 650 Phase 2 trial evaluating nivolumab plus ipilimumab, ipilimumab alone, and cabazitaxel in …
-
CLINICAL_TRIALS trial_result · 2023-04-20Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) [Phase 3]
Phase 3 trial evaluating pembrolizumab plus olaparib versus abiraterone acetate or enzalutamide in metastatic castration-resistant prostate …
-
CLINICAL_TRIALS trial_result · 2023-04-19Clinical Trial Update: A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP) [Phase 2, Phase 3]
Phase II/Phase III clinical trial evaluating intravenous melphalan with autologous whole blood stem cell transplantation in castration-resis…
-
CLINICAL_TRIALS trial_result · 2023-04-10Clinical Trial Update: Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer [Phase 3]
Phase 3 clinical trial update comparing ipatasertib plus abiraterone plus prednisone/prednisolone vs placebo plus abiraterone plus prednison…
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide. [Phase 3]
A Phase 3 trial comparing docetaxel versus hormone therapy as second-line treatment for asymptomatic or oligosymptomatic metastatic castrati…
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199) [Phase 2]
A Phase 2 study of pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer has completed and results ha…
-
FDA approval · 2023-03-23FDA Approved: ABIRATERONE ACETATE — Original Application (Florida Pharmaceutical Products, LLC)
FDA approved an abbreviated new drug application for a generic version of abiraterone acetate from Florida Pharmaceutical Products, LLC, for…
-
CLINICAL_TRIALS trial_result · 2022-12-13Clinical Trial Update: Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC [Phase 1, Phase 2]
An update on a Phase I dose-escalation study of fractionated 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer …
-
CLINICAL_TRIALS trial_result · 2022-12-06Clinical Trial Update: Phase I Trial of 225Ac-J591 in Patients With mCRPC [Phase 1]
Phase I trial evaluating Actinium-225 labeled J591 (225Ac-J591) in metastatic castration-resistant prostate cancer has completed enrollment …
-
CLINICAL_TRIALS trial_result · 2022-11-17Clinical Trial Update: Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway [Phase 2]
Phase 2 trial evaluating docetaxel and carboplatin in metastatic castration-resistant prostate cancer with BRCA1/2 pathway inactivation; stu…
-
CLINICAL_TRIALS trial_result · 2022-11-15Clinical Trial Update: Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer [Phase 2]
Phase 2 trial evaluating pembrolizumab and HER2Bi-armed activated T cells for metastatic castration-resistant prostate cancer has completed …
-
CLINICAL_TRIALS trial_result · 2022-11-08Clinical Trial Update: Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer [Phase 2]
Phase 2 trial evaluating abiraterone acetate without exogenous glucocorticoids in men with castration-resistant prostate cancer; results com…
-
CLINICAL_TRIALS trial_result · 2022-10-07Clinical Trial Update: A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients [Phase 3]
Phase 3 trial comparing ARB with Radium-223 versus ARB with placebo in metastatic castration-resistant prostate cancer was terminated; resul…
-
CLINICAL_TRIALS research · 2022-09-29Clinical Trial Update: A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer [Phase 2]
Phase 2 biomarker study evaluating standard-of-care Radium-223 chloride in metastatic castration-resistant prostate cancer; study completed …
-
FDA approval · 2022-09-02FDA Approved: ABIRATERONE ACETATE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
The FDA approved a supplemental application for abiraterone acetate (ABIRATERONE) from Amneal Pharmaceuticals NY LLC, authorizing changes to…
-
FDA approval · 2022-09-02FDA Approved: ABIRATERONE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for Abiraterone acetate (ANDA 210686) from BluePoint Laboratories, authorizing the continued manufac…